Bis(2,5-dioxopyrrolidin-1-yl) 2,2'-oxydiacetate

Catalog No. :
ACOUAZ761
CAS No. :
373614-12-1
Molecular Formula :
C12H12N2O9
Molecular Weight :
328.23

IUPAC Name:bis(2,5-dioxopyrrolidin-1-yl) 2,2'-oxydiacetate

Bis(2,5-dioxopyrrolidin-1-yl) 2,2'-oxydiacetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$74.00Login to see priceIn stockInquiry
1g97%$169.00Login to see priceIn stockInquiry
5g97%$687.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBis(2,5-dioxopyrrolidin-1-yl) 2,2'-oxydiacetate
IUPAC Namebis(2,5-dioxopyrrolidin-1-yl) 2,2'-oxydiacetate
MDL No.MFCD13184975
Molecular FormulaC12H12N2O9
Molecular Weight328.23
SMILESO=C(ON1C(CCC1=O)=O)COCC(ON2C(CCC2=O)=O)=O
InChI KeyPTIALSJRKNBZIO-UHFFFAOYSA-N
Synonym2,5-DIOXOPYRROLIDIN-1-YL 2-{2-[(2,5-DIOXOPYRROLIDIN-1-YL)OXY]-2-OXOETHOXY}ACETATE | BIS-N-SUCCINIMIDYL DIGLYCOLIC ACID | YPA61412 | 1,1'-{Oxybis[(1-oxoethane-2,1-diyl)oxy]}di(pyrrolidine-2,5-dione) | F87913 | SCHEMBL2568708 | D5512 | US10543207, Example 1
CAS No.373614-12-1
PubChem CID51340992

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACOUAZ761 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLGQM563 route compound structure diagram
    ACLGQM563110-99-6 In Stock
  2. Then
  3. ACOUAZ761 route product structure diagram
    ACOUAZ761373614-12-1 In Stock
Inquiry

2. ACOUAZ761 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOUAZ761 route product structure diagram
    ACOUAZ761373614-12-1 In Stock
Inquiry

Comments (0)